Panel Discussion: Industry Leader Perspectives on Inflammasome Therapeutic Development & Commercialization

Time: 8:30 am
day: Day Two


  • Exploring recent deals in the space: How to raise capital, attract investors and large pharma interest
  • Thinking outside the box when it comes to prioritizing specific disease indications for specific inflammasome therapeutics
  • How to balance commercial considerations of drug development with unmet need across diseases?
  • How crucial is it to demonstrate differentiation from standards of care or other inflammasome inhibitors to
    regulators and investors?
  • Should you plan for comparative data with standards of care in preclinical models before selecting indications
    and comparing across modalities?
  • Thoughts on evidence that activation of more than one type of NLR is pathogenic – are people going to take
    different directions to drug development now?